

## Artigo Destaque\_SPN2007

### *Molecular Neurobiology*

#### **Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease**

*Outeiro TE, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG. Science. 2007 Jul 27;317(5837):516-9. Epub 2007 Jun 21. PMID: 17588900*



Tiago Fleming Outeiro

Unidade de Neurociência Celular e Molecular  
Instituto de Fisiologia, Faculdade de Medicina da Universidade de Lisboa  
Av. Prof. Egas Moniz  
1649-028 Lisboa

Tel.: +351 217 999 438  
Fax: +351 217 999 436  
Email: [touteiro@gmail.com](mailto:touteiro@gmail.com)  
[www.imm.ul.pt](http://www.imm.ul.pt)

Tiago Outeiro graduated in Biochemistry at the University of Porto and was an Erasmus student at the University of Leeds in the UK. Tiago then did his PhD thesis at the Whitehead Institute for Biomedical research – MIT. Next, he worked at FoldRx Pharmaceuticals as a Research Scientist and Consultant. His work consisted of transferring the technology he developed and patented during his PhD.

Tiago was a Research Fellow in the Department of Neurology of the Massachusetts General Hospital – Harvard Medical School where he focused on the study of Neurodegenerative disorders such as Parkinson's and Alzheimer's disease.

Tiago has given several invited lectures in the USA and in Portugal and has organized several international scientific meetings both in Portugal and abroad. He served as an expert evaluator for the VI and VII Framework Programs of the European Commission.

Tiago served as President of PAPS in 2005-2006, and chairman in 2006-2007 of PAPS. He is currently the vice-President of the International Forum of Portuguese Investigators (FIIP) and a sub-director of "Ciência Hoje" ([www.cienciahoje.pt](http://www.cienciahoje.pt)).

Tiago heads the Cellular and Molecular Neuroscience Unit at the IMM where his group studies the molecular basis of neurodegenerative disorders with the goal of developing novel therapeutics. He also maintains a visiting scientist position at the Massachusetts General Hospital, Harvard Medical School, USA. His work is currently funded by the Gulbenkian Foundation and the Michael J. Fox Foundation in the USA.